Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

Harvard Medical School researchers have uncovered crucial insights into how an emerging class of antiviral drugs works.

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...